Arkolith/Insider Trading/INMB/Form 4

Moss David J

Chief Executive Officer, DirectorInmune Bio, Inc. (INMB) · full profile →Form 4 · filed Nov 18, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
16
0 non-derivative · 16 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 18, 2025Disposed to issuer(D)160K——0
Nov 18, 2025Grant(A)160K——160K
Nov 18, 2025Disposed to issuer(D)130K——0
Nov 18, 2025Grant(A)130K——130K
Nov 18, 2025Disposed to issuer(D)223K——0
Nov 18, 2025Grant(A)223K——223K
Nov 18, 2025Disposed to issuer(D)160K——0
Nov 18, 2025Grant(A)160K——160K
Nov 18, 2025Disposed to issuer(D)400K——0
Nov 18, 2025Grant(A)400K——400K
Nov 18, 2025Disposed to issuer(D)59K——0
Nov 18, 2025Grant(A)59K——59K
Nov 18, 2025Disposed to issuer(D)275K——0
Nov 18, 2025Grant(A)275K——275K
Nov 18, 2025Disposed to issuer(D)71K——0
Nov 18, 2025Grant(A)71K——71K

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-25-112239) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML